BACKGROUND: In patients with a malignant hypertension, immediate parenteral treatment with blood pressure-lowering agents such as intravenous sodium nitroprusside (SNP) is indicated. In this study, we evaluated static and dynamic cerebral autoregulation (CA) during acute blood pressure lowering with SNP in these patients. METHODS AND RESULTS: In 8 patients with mean arterial pressure (MAP) >140 mm Hg and grade III or IV hypertensive retinopathy at hospital admission, middle cerebral artery blood velocity (MCA V) and blood pressure were monitored. Dynamic CA was expressed as the 0.1-Hz MCA V(mean) to MAP phase lead and static CA as the MCA V(mean) to MAP relationship during SNP treatment. Eight normotensive subjects served as a reference group. In the patients, the MCA V(mean) to MAP phase lead was lower (30+/-8 degrees versus 58+/-5 degrees , mean+/-SEM; P<0.05), whereas the transfer gain tended to be higher. During SNP treatment, target MAP was reached within 90 minutes in all patients. The MCA V(mean) decrease was 22+/-4%, along with a 27+/-3% reduction in MAP (from 166+/-4 to 121+/-6 mm Hg; P<0.05) in a linear fashion (averaged slope, 0.82+/-0.15% cm x s(-1) . % mm Hg(-1); r=0.70+/-0.07). CONCLUSIONS: In patients with malignant hypertension, dynamic CA is impaired. An MCA V(mean) plateau was not detected during the whole SNP treatment, indicating loss of static CA as well. This study showed that during the whole rapid reduction in blood pressure with SNP, MCA V(mean) decreases almost one on one with MAP.
BACKGROUND: In patients with a malignant hypertension, immediate parenteral treatment with blood pressure-lowering agents such as intravenous sodium nitroprusside (SNP) is indicated. In this study, we evaluated static and dynamic cerebral autoregulation (CA) during acute blood pressure lowering with SNP in these patients. METHODS AND RESULTS: In 8 patients with mean arterial pressure (MAP) >140 mm Hg and grade III or IV hypertensive retinopathy at hospital admission, middle cerebral artery blood velocity (MCA V) and blood pressure were monitored. Dynamic CA was expressed as the 0.1-Hz MCA V(mean) to MAP phase lead and static CA as the MCA V(mean) to MAP relationship during SNP treatment. Eight normotensive subjects served as a reference group. In the patients, the MCA V(mean) to MAP phase lead was lower (30+/-8 degrees versus 58+/-5 degrees , mean+/-SEM; P<0.05), whereas the transfer gain tended to be higher. During SNP treatment, target MAP was reached within 90 minutes in all patients. The MCA V(mean) decrease was 22+/-4%, along with a 27+/-3% reduction in MAP (from 166+/-4 to 121+/-6 mm Hg; P<0.05) in a linear fashion (averaged slope, 0.82+/-0.15% cm x s(-1) . % mm Hg(-1); r=0.70+/-0.07). CONCLUSIONS: In patients with malignant hypertension, dynamic CA is impaired. An MCA V(mean) plateau was not detected during the whole SNP treatment, indicating loss of static CA as well. This study showed that during the whole rapid reduction in blood pressure with SNP, MCA V(mean) decreases almost one on one with MAP.
Authors: Enrico Sorrentino; Karol P Budohoski; Magdalena Kasprowicz; Peter Smielewski; Basil Matta; John D Pickard; Marek Czosnyka Journal: Neurocrit Care Date: 2011-04 Impact factor: 3.210
Authors: Michael L Alosco; John Gunstad; Xiaomeng Xu; Uraina S Clark; Donald R Labbe; Hannah H Riskin-Jones; Gretel Terrero; Nicolette F Schwarz; Edward G Walsh; Athena Poppas; Ronald A Cohen; Lawrence H Sweet Journal: J Am Soc Hypertens Date: 2014-04-13
Authors: Marine Poittevin; Pierre Lozeron; Rose Hilal; Bernard I Levy; Tatiana Merkulova-Rainon; Nathalie Kubis Journal: Transl Stroke Res Date: 2013-11-22 Impact factor: 6.829
Authors: Linda A Allen; James R Schmidt; Christopher T Thompson; Brian E Carlson; Daniel A Beard; Julian H Lombard Journal: Microcirculation Date: 2019-01-15 Impact factor: 2.628
Authors: J M Pollock; C T Whitlow; A R Deibler; H Tan; J H Burdette; R A Kraft; J A Maldjian Journal: AJNR Am J Neuroradiol Date: 2008-05-01 Impact factor: 3.825